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Exploring the Impact of Adding a
Respiratory Dimension to the EQ-5D-5L
Martine Hoogendoorn, Mark Oppe, Melinde R. S. Boland, Lucas M. A. Goossens ,
Elly A. Stolk, and Maureen P. M. H. Rutten–van Mo¨lken
Objectives. To evaluate the impact of adding a respiratory dimension (a bolt-on dimension) to the EQ-5D-5L health
state valuations. Methods. Based on extensive regression and principal component analyses, 2 respiratory bolt-on
candidates were formulated: R1, limitations in physical activities due to shortness of breath, and R2, breathing prob-
lems. Valuation interviews for the selected bolt-ons were performed with a representative sample from the Dutch
general public using the standardized interview protocol and software of the EuroQol group. Hybrid models based
on the combined time-tradeoff (TTO) and discrete choice experiment (DCE) data were estimated to assess whether
the 5 levels of the respiratory bolt-on led to significant changes in utility values. Results. For each bolt-on candidate,
slightly more than 200 valuation interviews were conducted. Mean TTO values and DCE choice probabilities for
health states with a level 4 or 5 for the respiratory dimension were significantly lower compared with the same health
states in the Dutch EQ-5D-5L valuation study without the respiratory dimension. Results of hybrid models showed
that for the bolt-on ‘‘limitations in physical activities,’’ the utility decrements were significant for level 3 (–0.055),
level 4 (–0.087), and level 5 (–0.135). For ‘‘breathing problems,’’ the utility decrements for the same levels were
greater (–0.086, –0.219, and –0.327, respectively). Conclusions. The addition of each of the 2 respiratory bolt-ons to
the EQ-5D-5L had a significant effect on the valuation of health states with severe levels for the bolt-on. The bolt-on
dimension ‘‘breathing problems’’ showed the greatest utility decrements and therefore seems the most appropriate
respiratory bolt-on dimension.
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The EQ-5D is a generic health-related quality-of-life
instrument with a descriptive system that comprises 5
dimensions (mobility, self-care, usual activities, pain/dis-
comfort, and anxiety/depression), each of which has
either 3 or 5 levels of severity. Although the EQ-5D is
often used in respiratory diseases, such as asthma and
chronic obstructive pulmonary disease (COPD),1–3
important aspects of these diseases are not included in
the current 5 dimensions of the EQ-5D. Shortness of
breath, coughing, wheezing, and sputum production are
not well captured by the EQ-5D domain pain and dis-
comfort, nor is the impact of these symptoms and other
problems frequently experienced by patients with respira-
tory diseases such as fatigue, poor sleep, and impaired
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sexual activity. As a result, the responsiveness of the EQ-
5D to clinically relevant within-subject change in COPD
and asthma over time appears limited,4,5 unless patients
have a serious exacerbation. Several trial-based economic
evaluations in COPD reported significant and relevant
improvements in clinical and patient-reported outcomes,
which were not reflected in significant improvements in
terms of quality-adjusted life-years (QALYs).6–10 In these
studies, the 3-level version of the EQ-5D was used.
A possible solution to improve the responsiveness of
the EQ-5D in respiratory diseases might be to use the
recently developed EQ-5D with 5 instead of 3 severity
levels for each dimension. However, a study by Nolan
et al.11 showed that the 8-week change in utility score for
COPD patients receiving pulmonary rehabilitation based
on the EQ-5D-5L was still weakly correlated with the
clinically relevant observed changes in disease-specific
outcomes. Ceiling effects (i.e., substantial proportions of
patients reporting the best scores on a dimension even
among severe patients) were also not improved much by
using the EQ-5D-5L instead of the EQ-5D-3L, 7% ver-
sus 8.5%, respectively.12
Another solution for the low responsiveness of the
EQ-5D in respiratory diseases would be the addition of a
respiratory dimension to the current descriptive system
of the EQ-5D. Such a bolt-on dimension could be rele-
vant not only for respiratory diseases but also for other
disease areas in which respiratory symptoms such as
shortness of breath play an important role, like cardio-
vascular and metabolic diseases. Several previous studies
identified gaps in the descriptive system of the EQ-5D
and explored the impact of bolt-on dimensions such as
cognition, concentration, energy, skin issues, vision,
sleep, and so forth,13–22 but the impact of a respiratory
bolt-on has not been studied before. Results of the previ-
ous bolt-on studies varied, but in general, the impact of a
bolt-on on the utility value seems to depend on the sever-
ity of the EQ-5D health state in combination with the
level of the bolt-on dimension. Adding bolt-on dimen-
sions to the EQ-5D could be a means to improve its
responsiveness, but comparability of the results to other
diseases/conditions is reduced.
The aim of the current study was to investigate the
potential value of a respiratory bolt-on. While the value
of a bolt-on ultimately depends on many criteria, in this
methodological research, we focused on the development
of candidate bolt-on items and the relative contribution
of these bolt-ons to the overall utility of health states.
Methods
Development of the Respiratory Bolt-on
To identify which of the respiratory complaints of
asthma and COPD patients was the most promising can-
didate for a respiratory bolt-on, 3 different approaches
were used. First, a content review of the EQ-5D and 6
disease-specific health-related quality-of-life measures
for asthma and COPD was performed. Disease-specific
questionnaires included in this content review were
the Asthma Quality of Life Questionnaire (AQLQ),23
the Asthma Control Questionnaire (ACQ),24 the St.
George’s Respiratory Questionnaire (SGRQ),25 the
COPD Assessment Test,26 the Clinical COPD
Questionnaire (CCQ),27 and the Modified Medical
Research Council (mMRC) Dyspnea Scale.28 Second, a
post hoc analysis of data from 3 large clinical studies in
asthma and COPD, which included both the EQ-5D-3L
and a disease-specific quality-of-life measure, was under-
taken.29–31 Multivariate regression analyses were per-
formed to investigate how much the proportion of
explained variance in EQ-5D visual analog scale (VAS)
scores (i.e., the R2) increased when respiratory items of
the different disease-specific questionnaires were added
to the EQ-5D dimension scores. Linear regression was
performed using the EQ-5D VAS score as a dependent
variable and 2 dummy variables for each of the 5 differ-
ent EQ-5D dimensions as independent variables (i.e., the
standard model). After that, the same regression model
was run plus 1 respiratory item/question. The R2 of the
model, including the respiratory item/question, was com-
pared with the R2 of the standard model to explore how
much additional variance was explained by the respira-
tory item. The third approach to identify promising can-
didates for a bolt-on consisted of a principal component
analysis (PCA) for the disease-specific health-related
quality-of-life questionnaires in combination with the
EQ-5D to investigate which items from the question-
naires form different constructs apart from the EQ-5D
domains.
After selection of the 2 most promising respiratory
candidate items (labeled R1 and R2), the items and levels
were phrased such that they were in line with the word-
ing of the EQ-5D-5L items. The final wording of the 2
respiratory candidate items was tested for clarity, com-
prehensiveness, and relevance in think-aloud sessions
with patients with asthma (n = 5) and COPD (n = 6)
and healthy members of the general population (n= 5).
394 Medical Decision Making 39(4)
Valuation Interviews
To explore the impact of the 2 bolt-on candidate items
on health state valuations, a pilot valuation study was
performed. Valuation interviews were performed with a
representative sample from the Dutch general public
aged at least 18 years. Quota sampling was applied to
ensure that the recruited panel was representative of the
Dutch population in terms of age, gender, and educa-
tional level. During individual interviews, participants
were asked to value different health states described in
terms of the dimensions of the EQ-5D-5L plus the
respiratory dimension. A split-sample design was used in
which half of the respondents were asked to value the
EQ-5D-5L + respiratory item 1 (EQ-5D-5L+R1) and
the other half of the respondents were asked to value the
EQ-5D-5L+ respiratory item 2 (EQ-5D-5L+R2).
Respondents were randomly assigned to 1 of the options.
During the valuation interviews, both the composite
time-tradeoff (TTO) and a discrete choice experiment
(DCE) were used to assess the impact of adding a respira-
tory bolt-on to the EQ-5D-5L on health state valuations.
The pilot valuation study used the EuroQol Valuation
Technology (EQ-VT) version 2.0, an updated version of
the EQ-VT protocol described by Oppe et al.32,33 The
valuation protocol was embedded in the EQ-VT plat-
form to create the computer-assisted personal interview
tool for use during the interviews and was accompanied
by standardized interviewer training materials and inter-
viewer scripts. The updated version of the EQ-VT included
3 changes compared with the original version aiming to
improve the quality of the data: 1) 3 practice c.q. test states
were added to the instructions of the TTO; 2) a feedback
module was included after the TTO, to allow respondents
to verify their answers and indicate any errors they made;
and 3) a quality control (QC) process was included, using
the QC tool, a software package purposely developed for
use alongside EQ-VT studies.34 The EQ-VT platform also
included the assignment of participants to sets of states
from the underlying blocked design, randomization proce-
dures, the iterative process in the TTO, and capturing and
time stamping the participants’ responses to all tasks.
The interviews were performed by 5 different inter-
viewers who received training on the EQ-VT software
and the valuation protocol in advance. In addition, the
performance of the interviewers was continuously
assessed throughout the entire period of data collection
using the QC tool.
Recruited participants were invited to come to 1 of
the 2 interview locations for an individual interview.
After a brief introduction of the purpose of the research,
respondents were asked to complete the descriptive part
of the EQ-5D-5L with the respiratory bolt-on and the
EQ VAS as well as standard questions regarding age,
sex, and experience with illness included in the EQ-VT.
The third part consisted of valuation of the selected
health states using the composite TTO technique.35 After
extensive explanation of the TTO task, respondents prac-
ticed 3 health states, a mild, severe, and moderate state,
to get familiar with the range of severity of the health
states included in the task. Respondents were asked to
consider 2 alternatives: 1) having a particular health state
for 10 years or 2) living in perfect health with a shorter
duration than 10 years, both followed by immediate
death. The duration in perfect health was decreased or
increased until the respondent indicated he or she was
indifferent between the 2 alternatives. The utility for the
health state at the point of indifference between the 2
alternatives was given by x/10, where x is 10 minus the
maximum tradeoff. When respondents exchanged all 10
years in perfect health (i.e., the health state is worse than
death), the ‘‘trading time in perfect health’’ was increased
to 20 years. The health state being evaluated still lasted
for 10 years but was preceded by a period of 10 years in
full health (so-called lead time TTO).36 Respondents
could indicate how much time of the 20 years in full
health they were willing to trade so that when valuing
very poor states, respondents could trade off more than
10 years and express negative utility values. The end of
the TTO task included a feedback module in which the
rank order of the valued health states was presented to
the respondents. Health states were presented in descend-
ing order, starting with the highest valued health state.
Health states with the same valuation were presented
next to each other. Respondents were asked to check the
rank order. If the respondent indicated that a health
state was positioned incorrectly in the rank order, that
health state was ‘‘flagged.’’ Because it was not possible to
correct the order of the ‘‘flagged’’ states in the feedback
module, the ‘‘flagged’’ states were excluded in the analy-
sis phase of the study. The fourth part was the valuation
task using DCE questions. The health states that were
valued with DCE questions were different from the
states that were valued with the TTO. For the DCE task,
respondents had to indicate which health state, state A
or state B, they considered the better health state. A
number of cognitive debriefing questions were completed
both after the TTO as well as the DCE part. For the cur-
rent study, a separate questionnaire including detailed
background questions on education, income, marital sta-
tus, and experience with lung diseases was also com-
pleted. Participants received a 25 Euro compensation for
their participation.
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Definition of the Reference (=Comparator)
Because for the current valuation study, the same metho-
dology was used as in the Dutch EQ-5D-5L valuation
study and respondents were sampled in a similar way, it
was planned to compare the results of the current study
to the results of the Dutch EQ-5D-5L valuation study
without the respiratory dimension.37 The subset of TTO
states and DCE pairs that matched those in the current
bolt-on valuation study (see below) was selected from the
total data set of the Dutch EQ-5D-5L valuation study
and used for comparison with the results of the valuation
study, including the respiratory bolt-on. A caveat of this
comparison is that the Dutch EQ-5D-5L study was done
with version 1.0 of the EQ-VT, which did not include the
3 practice states for the TTO, the feedback module for
the TTO, and the QC tool.
Selection of Health States
The health states that were included in the current study
were a subset of health states included in the Dutch EQ-
5D-5L valuation study (Dutch EQ-VT states). In this
way, it could be guaranteed that the descriptive results of
the current bolt-on study could be compared directly
with those of the Dutch EQ-5D-5L valuation study.38
For the current study, we aimed for 200 respondents for
each of the 2 arms (i.e., R1 and R2). Each arm included
the same 2 blocks of 10 states for the TTO task and 4
blocks of 10 pairs for the DCE task. Each individual
respondent completed 10 TTO questions and 10 DCE
questions. To achieve the recommended 100 observa-
tions per state,39 in total 200 respondents were needed
for each bolt-on.
For the selection of the TTO states, 3 criteria were
taken into account: utility balance, reasonable level bal-
ance, and a fractional addition of the respiratory dimen-
sion. Like in the EQ-VT TTO design, each block of 10
questions contained 1 very mild state (with only 1
domain at level 2, all others at level 1) and the worst pos-
sible health state (i.e., 55555+R). These states were
selected manually, as was the addition of the sixth
domain (the Respiratory dimension) for these states. The
16 remaining TTO states were selected as a subset of the
TTO design of the EQ-VT complemented with the
respiratory dimension. To increase the utility balance,
the Dutch EQ-VT states were first stratified by utility in
7 strata, and mild, moderate, and severe levels of the
bolt-ons were added to the states selected in each
stratum.
The 40 pairs for the DCE were chosen as a subset of
the 196 pair design of the EQ-VT complemented with the
respiratory dimension. A Bayesian D-efficient design
algorithm was used to generate the design for the DCE,
using the Dutch EQ-VT data as priors for the 5 dimen-
sions of the EQ-5D. The prior for the respiratory bolt-
ons was based on the average of the first 3 EQ-5D dimen-
sions (i.e., mobility, self-care, and usual activities) but
with increased uncertainty surrounding the priors.
Statistical Analysis
The first part of the statistical analyses consisted of the
descriptive analyses, including characteristics of respon-
dents, mean TTO-based utility values, and choice prob-
abilities based on the DCE. For each health state, the
mean scores were compared between the 2 different bolt-
ons and between the bolt-ons and the subset of the
Dutch valuation study (=comparator) using t tests to
see whether differences were statistically significant.
DCE results were presented as the probability that a cer-
tain health state was chosen, and chi-square tests were
used to test differences between probabilities.
In the second part of the analyses, so-called hybrid
models based on the combined TTO and DCE data were
estimated. For the 2 bolt-on arms, basic hybrid models
were estimated in which a normal distribution was
assumed for the TTO data and a conditional logistic dis-
tribution for the DCE data, following Ramos-Gon˜i
et al.38 The hybrid models were estimated using Stata 14
and the hyreg command.40 For all analyses, a P value
less than 0.05 was considered statistically significant.
Results
Development of the Respiratory Bolt-on
Extensive results of the content review and the post hoc
regression analyses to determine the most promising
respiratory item to include in a bolt-on are presented in
detail in an online supplement. In summary, results of
the content review showed that all disease-specific ques-
tionnaires include questions about the impact of asthma/
breathlessness on physical activities (Supplementary
Table A1). The EQ-5D includes an item that describes
the impact on physical activities in terms of the impact
on mobility. Five of the disease-specific questionnaires
address asthma or COPD-specific symptoms, while the
EQ-5D addresses symptoms more broadly in terms of
pain/discomfort. Impact on daily functioning was
included in 4 disease-specific questionnaires as well as the
EQ-5D. Dimensions that were included in several
disease-specific questionnaires, but not in the EQ-5D,
were impact on sleep and use of medication. The post
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hoc regression analyses showed that the explained var-
iance in the EQ-5D VAS score improved most when
items on the impact of asthma or breathlessness on physi-
cal activities from the ACQ, AQLQ, CCQ, or mMRC
were added to the EQ-5D dimension scores. For the
SGRQ, adding items about the impact of the chest condi-
tion to the EQ-5D dimension scores resulted in the high-
est increase in the explained variance (Supplementary
Table A2 to A6). Results of the PCA showed that for
multiple questionnaires, separate constructs were found
on which none of the EQ-5D items loaded. These con-
structs related either to symptoms or to the impact of
breathlessness on activities. Based on the combined
results of the post hoc regression analyses and the PCA,
we concluded that symptoms and the impact of shortness
of breath on physical activities were the 2 most appropri-
ate items/domains for inclusion in the respiratory bolt-on.
Several possible formulations of the new respiratory
bolt-on were tested for clarity, comprehensiveness, and
relevance, and the final wording of the 2 bolt-ons items
were as follows:
R1: Limitations in physical activities due to shortness of
breath (e.g., climbing stairs, going for a walk, carrying
things, gardening):
 I have no problems with physical activities due to my
shortness of breath.
 I have slight problems with physical activities due to
my shortness of breath.
 I have moderate problems with physical activities due
to my shortness of breath.
 I have severe problems with physical activities due to
my shortness of breath.
 I am unable to do physical activities due to my short-
ness of breath.
R2: Breathing problems (e.g., shortness of breath,
wheezing, coughing, sputum):
 I have no breathing problems.
 I have slight breathing problems.
 I have moderate breathing problems.
 I have severe breathing problems.
 I have extreme breathing problems.
With regard to the relevance of the items, patients consid-
ered a question on the impact of shortness of breath on
their ability to perform physical activities highly relevant
and important. However, they thought that the added
value of such an item to the existing questions of the EQ-
5D was limited. A question about symptoms was regarded
to have less importance but was considered to have no
overlap with the existing questions of the EQ-5D. Based
on these findings, both candidate respiratory bolt-ons were
included in the pilot valuation study to determine which of
the 2 items had the most impact on the valuation.
Valuation Study of the Respiratory Bolt-on
In total, 430 valuation interviews were completed: 221
for bolt-on R1 (i.e., limitations in physical activities due
to shortness of breath) and 209 for bolt-on R2 (i.e.,
breathing problems). Data were collected in the spring
and summer of 2015. In total, 989 completed interviews
from the Dutch EQ-5D-5L valuation study were avail-
able to use as reference (=comparator). Table 1 shows
the characteristics of the respondents. Half of the respon-
dents were male. The mean age was about 47 years, and
the mean EQ-VAS score for own health was about 80.
About a quarter of the respondents had experienced a
severe disease themselves. The characteristics of the
respondents valuing R1 and the respondents valuing R2
were not statistically significantly different, although
respondents valuing R2 tended to have slightly more
health problems themselves and seemed to have some-
what more experience with severe disease. Participants in
the current bolt-on study were comparable to the partici-
pants in the Dutch EQ-5D-5L study with respect to per-
centage of males, mean age, and EQ-5D VAS score.
During the interviews, a QC report was produced on a
weekly basis to check whether all interviewers were using
the interview protocol correctly and to standardize the
interviews as much as possible between different inter-
viewers. The final report showed that the quality of the
interviews can be considered as ‘‘good’’ according to EQ-
VT standards.
TTO Values
TTO data of 4 respondents, 2 for each bolt-on, were
excluded from the analyses because respondents did not
understand the TTO task and the task was prematurely
terminated. During the feedback module, 8.4% of the
TTO observations were marked as ‘‘incorrectly positioned’’
in the rank order, and these observations were excluded
from the analyses. Results including the flagged states were
very similar to the ones excluding these flagged states.
Table 2 shows mean TTO values for the bolt-ons and,
as a reference, the values for the EQ-5D-5L states in the
Dutch EQ-5D-5L valuation study. For very mild health
states with no problems on the respiratory dimension
(e.g., state 112111), utility values for both bolt-ons were
higher compared with the reference values. Health states
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with levels 4 and 5 for the respiratory dimension resulted
in significantly lower utility values. Utility values did not
differ much between the 2 different bolt-ons. Only health
states with a level 5 for the respiratory dimension utility
values were significantly lower for bolt-on R2, the bolt-
on of breathing problems. Although the differences were
Table 1 Baseline Characteristics of the Different Groups of Respondents
Bolt-on R1 Bolt-on R2 Dutch EQ-5D-5L Valuation Study
Total N for analysis 221 209 990
Men, % 49.8 47.8 49.0
Age, mean (SD) 46.8 (15.9) 45.1 (15.2) 47.4 (16.8)
Problems with mobility,a % 19.9 23.9 25.6
Problems with self-care,a % 2.7 2.4 3.9
Problems with usual activities,a % 25.3 29.2 27.6
Pain/discomfort,a % 42.1 45.9 49.1
Anxiety/depression,a % 14.9 17.7 20.5
EQ VAS score, mean (SD) 81.5 (12.4) 79.2 (15.8) 80.6 (14.7)
Experience with severe disease, % yes
 Yourself 23.5 28.2 23.6
 Relatives 73.8 80.9 72.5
 Caring for others 38.9 47.4 33.6
Experience with lung disease, % yes
 Yourself 18.6 24.4 -
 Relatives 50.2 52.2 -
 Caring for others 24.9 31.1 -
aLevel 2 to 5.
Table 2 Differences between Mean TTO Values
P Value
Health
State
Bolt-on
R1a
Bolt-on
R2b
Reference (EQ-5D-5L
without Bolt-on)
Bolt-on R1 v.
Reference
Bolt-on R2 v.
Reference
Bolt-on R1 v.
Bolt-on R2
112111 0.958 0.969 0.925 0.03 0.002 0.34
133131 0.805 0.845 0.759 0.30 0.03 0.24
351431 0.275 0.229 0.330 0.50 0.26 0.63
315251 0.093 0.191 0.311 0.02 0.20 0.29
532441 –0.141 –0.065 0.059 0.02 0.18 0.42
111112 0.954 0.971 – – – 0.19
251222 0.643 0.694 0.601 0.55 0.18 0.41
441252 0.118 0.095 0.124 0.95 0.77 0.81
445532 –0.217 –0.205 –0.112 0.26 0.35 0.90
423213 0.679 0.682 0.689 0.85 0.90 0.96
323143 0.370 0.414 0.423 0.48 0.87 0.59
145543 –0.177 –0.130 –0.150 0.76 0.84 0.63
555553 –0.509 –0.580 –0.314 0.002 \0.001 0.40
534124 0.410 0.154 0.466 0.44 0.001 0.004
224344 0.120 0.082 0.305 0.02 0.008 0.66
214444 –0.052 –0.195 0.139 0.03 0.001 0.15
244454 –0.278 –0.423 –0.152 0.15 0.004 0.11
131225 0.678 0.418 0.808 0.01 \0.001 0.001
342325 0.440 0.193 0.603 0.02 \0.001 0.006
555555 –0.581 –0.581 –0.314 \0.001 \0.001 0.99
States are ordered by increasing level of the bolt-on dimension and within that by decreasing mean utility when including the bolt-on R1. Gray
cells indicate statistically significant differences.
aR1, limitations in physical activities due to shortness of breath.
bR2, breathing problems.
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not statistically significant at the 95% level, it seemed
that bolt-on R2 resulted in a wider range of utilities com-
pared with bolt-on R1. That is, the very mild states
showed systematically higher values, while the very
severe states showed systematically lower values than
bolt-on R1 (apart from the worst state 555555).
Choice Probabilities
Table 3 shows the choice probabilities for different pairs
of health states. In general, states with a level 1, no prob-
lems, for the respiratory dimension had a higher prob-
ability to be chosen as the better state than the same
state without respiratory dimension (=comparator). For
states with a level 4 or 5 for the respiratory dimension,
the probability to be chosen was lower compared with
the reference. That applied to both bolt-ons, but more so
for R2.
Hybrid Models
Table 4 shows the results of the hybrid models in which
both the TTO data and DCE data were combined. The
intercept shows the difference between the predicted
value for the mildest state defined as 111111 and the the-
oretical value for this state, equal to 1. It was not stati-
cally significant. Results of the hybrid models showed
that, in general, for both respiratory bolt-ons and the ref-
erence, coefficients decreased as the level increased. For
both respiratory bolt-ons R1 and R2, coefficients for the
levels 3, 4, and 5 for the respiratory dimensions were sta-
tistically significant, although for bolt-on R2 (on breath-
ing problems), the decrements were greater. For bolt-on
R2, but not for bolt-on R1, the utility decrements were
statistically significantly greater than the decrements of
the previous level from level 3 onward. The models for
bolt-on R1 and R2 resulted in 2 and 6 inconsistencies,
respectively. All inconsistencies except 1 were for levels 2
or 3, and the inconsistent coefficients were not signifi-
cantly different from zero. For bolt-on R2, the coefficient
for usual activities level 5 was nonsignificantly lower than
for level 4.
Discussion
The current study explored the potential room for add-
ing a respiratory bolt-on dimension to the EQ-5D-5L.
Based on combined results of quantitative analysis and
interviews with patients with a respiratory disease, 2 dif-
ferent bolt-on candidates were identified and included in
the valuation study: R1, limitations in physical activities
due to shortness of breath, and R2, breathing problems.
The largest utility decrements were associated with
the second bolt-on candidate. For bolt-on candidate R1,
the utility decrements were –0.055 for level 3, –0.087 for
level 4, and –0.135 for level 5, whereas for R2, they were
–0.086, –0.219, and –0.327, respectively. The decrements
compared with the previous level were statistically signif-
icant for bolt-on R2 but not for bolt-on R1. However,
the overall model for R2 showed more inconsistencies on
the other dimensions compared with the model for R1.
The inconsistencies mostly resulted from level 2 or 3 not
being different from level 1.
Results of the valuation part of this study seem to be
in line with previous bolt-on studies. In the current study,
mean TTO utility values for very mild states with a level
1 for the respiratory dimension were slightly higher com-
pared with the Dutch EQ-5D-5L study, while states with
a level 4 or 5 for the respiratory dimension were lower.
Similar results have been found by other researchers. A
study by Krabbe et al.13 that explored the impact of add-
ing a cognitive dimension to the EQ-5D-3L showed that
adding a good level of the bolt-on to a worse health state
did not result in an increase of the utility values, while a
bad level of the bolt-on added to worse health states
resulted in an additional reduction of the utility value.
Swinburn et al.17 showed that adding dimensions on skin
irritation and self-confidence to the EQ-5D-5L resulted
in significant utility decrements for levels 4 and 5 of both
bolt-ons. The overall conclusion of a study of Yang
et al.20 exploring the impact of bolt-ons on sleep, hearing
problems, and vision problems was that addition of a
level 1 for the bolt-on did not change or slightly increased
utility values. For severe levels of the bolt-on, utility val-
ues were reduced compared with the same health state
without bolt-on dimension.20
A strength of the current study was that the valuation
study was performed using the standardized EQ-VT soft-
ware and interview protocol. During the interview
period, weekly QC reports were made for the first 70%
of the data, to ensure that the interviewers followed the
protocol and to see whether there were large differences
in outcomes between interviewers. In this way, changes
to the interview techniques of the different interviewers
could be made in an early stage to make the interview
approach as uniform as possible.
A limitation of the current study was that we did not
create a completely new design for the study (i.e., the set
of TTO states and DCE pairs) but selected the TTO
states and DCE pairs based on subsets of those included
in the EQ-VT complemented with the respiratory dimen-
sion. This was done to allow for maximum comparability
of obtained responses with data from the Dutch EQ-5D-
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5L valuation study (i.e., comparing mean TTO values,
DCE choice probabilities, as well as the regression mod-
els). However, other designs potentially would have been
more efficient with respect to model identification and
estimation. Also, the fact that we collected TTO values
only for 20 states limited our modeling options, ruling
out the possibility of estimating a main effects TTO
model including parameters for all levels of the 6 dimen-
sions separately. This sufficed for the current study, in
which we could implement the hybrid model instead of a
TTO-only model, and with respect to our main aim to
see whether addition of the bolt-on had a significant
Table 3 Choice Probabilities for the Discrete Choice Experiment
P Value
Pairs
Bolt-on
R1a
Bolt-on
R2b
Reference (EQ-5D-5L
without Bolt-on)
Bolt-on R1 v.
Reference
Bolt-on R2 v.
Reference
Bolt-on R1 v.
Bolt-on R2
State A v. state B Probability state A was chosen
511311 - 353534 96.4 92.5 93.8 0.58 0.82 0.38
121511 - 355432 89.3 84.6 77.6 0.10 0.36 0.47
443231 - 215254 82.1 82.7 63.2 0.04 0.04 0.94
112121 - 221123 81.5 90.7 66.7 0.11 \0.01 0.16
235511 - 431355 73.2 69.2 43.8 \0.01 0.02 0.65
445211 - 411532 71.4 68.0 67.6 0.56 0.83 0.70
311351 - 114442 66.1 74.0 82.9 0.06 0.31 0.38
515521 - 355134 23.6 30.2 15.0 0.30 0.09 0.44
222222 - 255145 100 98.1 100 1.0 0.39 0.30
353212 - 532155 96.4 96.2 90.6 0.27 0.29 0.97
134322 - 132455 92.9 96.0 100 0.15 0.28 0.49
252122 - 324433 92.7 96.1 100 0.12 0.27 0.43
213352 - 445514 74.1 90.7 78.8 0.62 0.12 0.02
225442 - 354523 53.6 63.5 62.5 0.42 0.93 0.30
442342 - 334413 35.7 54.0 38.2 0.81 0.16 0.06
343452 - 513254 22.2 61.1 21.2 0.91 \0.001 \0.001
431413 - 255541 98.1 98.1 95.1 0.40 0.40 0.99
234423 - 254145 63.0 68.5 40.7 0.06 0.02 0.54
343333 - 331422 55.4 57.7 71.9 0.13 0.19 0.81
332253 - 533141 34.5 32.1 39.0 0.65 0.48 0.79
232353 - 111415 30.9 58.5 13.3 0.07 \0.001 0.004
152443 - 442415 30.4 62.0 34.1 0.69 \0.01 0.001
213543 - 413212 12.7 5.7 9.5 0.62 0.47 0.21
342553 - 352211 1.9 3.7 — — — 0.56
424214 - 542552 100 90.7 97.1 0.21 0.25 0.02
413124 - 242535 90.9 94.3 93.9 0.57 0.92 0.50
231224 - 124153 89.3 68.0 80.5 0.22 0.18 \0.01
511234 - 434512 69.6 61.5 88.9 0.06 0.01 0.38
541214 - 443223 46.3 24.1 60.7 0.22 0.001 0.02
135534 - 312343 27.8 5.6 36.7 0.40 \0.001 \0.01
344424 - 152141 10.9 9.4 37.0 \0.01 \0.01 0.80
414314 - 242122 8.9 8.0 11.4 0.70 0.59 0.86
225125 - 553133 67.9 38.0 86.0 0.04 \0.001 \0.01
155345 - 434541 67.3 58.5 90.7 \0.01 \0.001 0.35
231245 - 143141 33.9 17.3 68.6 0.001 \0.001 0.049
422555 - 555244 32.1 24.0 33.3 0.91 0.37 0.35
332245 - 421131 12.5 7.7 22.2 0.25 0.07 0.41
455155 - 344334 5.6 3.7 11.8 0.30 0.14 0.65
455425 - 421334 5.4 5.8 2.0 0.38 0.34 0.93
552445 - 535311 1.8 2.0 13.2 0.03 0.04 0.94
Pairs are ordered by increasing level of the bolt-on dimension in state A and within that by decreasing choice probability of the bolt-on R1. Gray
cells indicate statistically significant differences.
aR1, limitations in physical activities due to shortness of breath.
bR2, breathing problems.
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impact on the valuations and whether there were differ-
ences between the 2 selected bolt-ons. However, to come
up with a value set for the EQ-5D-5L+R, a design cre-
ated for that specific purpose should be used, which will
lead to better properties of the regression model (e.g.,
fewer inconsistent parameters). Depending on the type of
model used (i.e., TTO only or a hybrid), more health
states for TTO and/or pairs of health states for the DCE
are needed, in addition to a larger sample size.
In both the development and valuation part of the
study, we faced a number of issues. During the develop-
ment phase, we observed a discrepancy between the qua-
litative and quantitative data about the relative
importance of the 2 bolt-on candidates. Patients clearly
indicated that an item on the impact of shortness of
breath on the ability to perform physical activities was
highly relevant and more important than an item on
symptoms, even while they recognized that an item on
symptoms could have more added value compared with
the existing dimensions of the EQ-5D. The valuation
study confirmed the latter. This raises the question: what
is most important in the development of a bolt-on, rele-
vance or impact on valuation?
One could also argue that respiratory symptoms
might already be captured by the EQ-5D pain/discom-
fort dimension. However, in the PCA, items related to
respiratory symptoms did not load on the same construct
as the EQ-5D pain/discomfort item, and none of the
patients reported seeing an overlap with respiratory
symptoms and the pain/discomfort dimension of the
EQ-5D.
Furthermore, caution is warranted in comparing TTO
values for the bolt-ons with the reference scores from the
Dutch EQ-5D-5L valuation study, because the
Table 4 Coefficients Obtained from a Hybrid Model with Intercept
Bolt-on R1a Bolt-on R2b
Mean Sig. Sig. Inc. Mean Sig. Sig. Inc.
Intercept –0.019 –0.025
Mobility 2 –0.044 –0.087 c d
Mobility 3 –0.134 c d –0.120 c
Mobility 4 –0.194 c d –0.213 c d
Mobility 5 –0.258 c d –0.290 c d
Self-care 2 –0.024 –0.056
Self-care 3 –0.012 –0.035
Self-care 4 –0.112 c d –0.135 c d
Self-care 5 –0.141 c –0.135 c
Usual activities 2 0.013 0.014
Usual activities 3 –0.009 0.056
Usual activities 4 –0.161 c d –0.177 c d
Usual activities 5 –0.187 c –0.175 c
Pain/discomfort 2 –0.064 c d –0.085 c d
Pain/discomfort 3 –0.105 c –0.039
Pain/discomfort 4 –0.353 c d –0.330 c d
Pain/discomfort 5 –0.415 c d –0.434 c d
Anxiety/depression 2 –0.081 c d –0.085 c d
Anxiety/depression 3 –0.153 c d –0.160 c d
Anxiety/depression 4 –0.393 c d –0.325 c d
Anxiety/depression 5 –0.493 c d –0.390 c d
Respiratory dimension 2 –0.020 0.018
Respiratory dimension 3 –0.055 c –0.086 c d
Respiratory dimension 4 –0.087 c –0.219 c d
Respiratory dimension 5 –0.135 c –0.327 c d
Values in italic indicate a logically inconsistent parameter (e.g., self-care 3 problems result in a higher utility than self-care 2 problems).
aR1, limitations in physical activities due to shortness of breath.
bR2, breathing problems.
cThe decrement of the dummy is significantly different from zero at the 95% level.
dThe dummy is significant compared with the previous level (i.e., the increment of the dummy is different from zero at the 95% level). Level 2 is
compared with level 1 (by definition 0 in regression), level 3 with level 2, level 4 with level 3, and level 5 with level 4.
Note: Sig.: Significance of the coefficient; Sig. Inc.: Significance of the increment.
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comparison is made on a between-study basis, and the
current data were collected using a later version of the
EQ-VT protocol. In the updated EQ-VT protocol,
greater attention is given to the QC. It has been sug-
gested that QC reduces interviewer effects and clustering
of responses on certain values and increases protocol
compliance and the proportion of negative values.36
Although the impact of using the QC tool was found to
be less pronounced in the Netherlands compared with
Spain,36 the difference between protocols might have had
an impact on the comparison of the TTO values for
states with and without bolt-on.
Although adding a bolt-on/disease-specific dimension
to the EQ-5D-5L might be an option to improve the
responsiveness of the EQ-5D for certain diseases, the
main disadvantage of such an approach is that the com-
parability of the outcomes of the EQ-5D with other dis-
eases is reduced. Comparability between different
diseases is currently considered one of the strengths of
the EQ-5D, which raises the question as to whether it is
desirable to sacrifice comparability for better responsive-
ness. Instead of being an alternative to the standard EQ-
5D-5L, the EQ-5D-5L plus bolt-on could be used in
addition to the standard EQ-5D-5L to calculate so-called
‘‘bolt-on’’ QALYs next to the calculation of the standard
QALYs to show the potential change in treatment
impact when a disease- or symptom-specific domain is
included in the evaluation.
In conclusion, the current pilot valuation study showed
that the addition of a respiratory bolt-on about either
breathing problems or limitations in physical activities
due to shortness of breath to the EQ-5D-5L had a signifi-
cant effect on the valuation of health states for severe lev-
els of the bolt-on. The bolt-on dimension ‘‘breathing
problems’’ showed the greatest impact on health state
valuations and therefore seems the most appropriate
respiratory bolt-on dimension. However, before this bolt-
on can be included in studies to measure the health status
of patients, additional valuation interviews including more
health states need to be conducted to estimate a consistent
valuation set. Further research is also needed to investigate
whether the EQ-5D-5L+R is indeed more responsive to
change in health status of patients over time.
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